786 reports of this reaction
1.6% of all FOSAPREPITANT DIMEGLUMINE reports
#10 most reported adverse reaction
FEBRILE NEUTROPENIA is the #10 most commonly reported adverse reaction for FOSAPREPITANT DIMEGLUMINE, manufactured by Merck Sharp & Dohme LLC. There are 786 FDA adverse event reports linking FOSAPREPITANT DIMEGLUMINE to FEBRILE NEUTROPENIA. This represents approximately 1.6% of all 48,249 adverse event reports for this drug.
Patients taking FOSAPREPITANT DIMEGLUMINE who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is a less commonly reported adverse event for FOSAPREPITANT DIMEGLUMINE, but still significant enough to appear in the safety profile.
In addition to febrile neutropenia, the following adverse reactions have been reported for FOSAPREPITANT DIMEGLUMINE:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 786 FDA reports for FOSAPREPITANT DIMEGLUMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 1.6% of all adverse event reports for FOSAPREPITANT DIMEGLUMINE, making it a notable side effect.
If you experience febrile neutropenia while taking FOSAPREPITANT DIMEGLUMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.